Article Information
History
- December 21, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sangmoon Lee1,*,
- Jin Roh2,*,
- Jun Sung Park3,
- Islam Oguz Tuncay1,
- Wonchul Lee1,
- Jung-Ah Kim1,
- Brian Baek-Lok Oh1,
- Jong-Yeon Shin1,
- Jeong Seok Lee1,
- Young Seok Ju1,
- Ryul Kim1,
- Seongyeol Park1,
- Jaemo Koo1,
- Hansol Park1,
- Joonoh Lim1,
- Erin Connolly-Strong1,
- Tae-Hwan Kim4,
- Yong Won Choi4,
- Mi Sun Ahn4,
- Hyun Woo Lee4,
- Seokhwi Kim2,
- Jang-Hee Kim2 and
- Minsuk Kwon4,#
- 1Genome Insight Inc., San Diego. CA, USA
- 2Department of Pathology, Ajou University School of Medicine, Suwon, Korea
- 3Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea
- 4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
- ↵#Corresponding Author
Minsuk Kwon, M.D., Ph.D. Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea Tel: +82-31-219-5488, Fax: +82-31-219-5983 Email: mskwon{at}ajou.ac.kr
↵* These authors contributed equally to this work.
Posted December 21, 2023.
Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel
